Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY ; volume:18 ; number:1 ; day:6 ; month:10 ; year:2016 ; pages:1-12 ; date:12.2016
Arthritis Research & Therapy ; 18, Heft 1 (6.10.2016), 1-12, 12.2016
- Urheber
-
Boyapati, Anita
- Beteiligte Personen und Organisationen
-
Msihid, Jérôme
Fiore, Stefano
van Adelsberg, Janet
Graham, Neil M. H.
Hamilton, Jennifer D.
SpringerLink (Online service)
- DOI
-
10.1186/s13075-016-1132-9
- URN
-
urn:nbn:de:1111-2016110610898
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Boyapati, Anita
- Msihid, Jérôme
- Fiore, Stefano
- van Adelsberg, Janet
- Graham, Neil M. H.
- Hamilton, Jennifer D.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Methotrexate
High-dose Methotrexate
METHOTREXATE INDUCED LEUCOENCEPHALOPATHY
Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial
Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis
Methotrexate intolerance in Rheumatoid Arthritis
Potential neurotoxicity associated with methotrexate
Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
Methotrexate-Related Pancytopenia: A Case Report
Methotrexate-Associated Lymphoproliferative Disorder: Dermoscopic Features
Low-dose oral methotrexate-induced crystalluria
Methotrexate
High-dose Methotrexate
METHOTREXATE INDUCED LEUCOENCEPHALOPATHY
Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial
Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis
Methotrexate intolerance in Rheumatoid Arthritis
Potential neurotoxicity associated with methotrexate
Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
Methotrexate-Related Pancytopenia: A Case Report
Methotrexate-Associated Lymphoproliferative Disorder: Dermoscopic Features
Low-dose oral methotrexate-induced crystalluria
Methotrexate
High-dose Methotrexate
METHOTREXATE INDUCED LEUCOENCEPHALOPATHY
Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial
Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis
Methotrexate intolerance in Rheumatoid Arthritis
Potential neurotoxicity associated with methotrexate
Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
Methotrexate-Related Pancytopenia: A Case Report
Methotrexate-Associated Lymphoproliferative Disorder: Dermoscopic Features